Lenacapavir
latest news & developments
Somebody call Hasina
Amid the mostly depressing HIV headlines of recent times, concerned as they mainly are with the deadly impacts of donor defunding, South Africa’s imminent roll-out of a…
Our anti-HIV jab will be rolled out in six weeks. But funding cuts hollowed out the system needed to deliver it
The uptake of the once-every-six-month HIV prevention jab lenacapavir (LEN) in South Africa will be heavily affected by the Trump administration’s funding cuts to the country, a…
180 000 infections in 2024, 47 000 by 2045 — if SA rolls out the twice-a-year HIV prevention jab fast enough
The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics.…
What will HIV funding look like in 2026?
After a year of US funding cuts across global public health, including South Africa’s hard-hit HIV programmes, new realities are settling in
Here’s what’s on South Africa’s 2026 public health agenda
We talked to experts in obesity, tobacco, artificial intelligence, HIV, TB and the NHI to find out what we can expect — and what we can’t — this year
SA’s first batch of LEN jabs will arrive in February. Use Bhekisisa’s dashboard to find out who should get them
Who should get what slice of the pie once the medicine is available in public clinics? And are numbers alone what would drive decisions?
SA wants to make its own six-monthly HIV prevention jabs by 2027. But there’s a hitch
None of the companies that will be involved have a licence from the inventor of Lenacapavir, Gilead Sciences, to make the jab
The six-monthly anti-HIV jab could be in 360 clinics by February. Who should get the first doses?
The country’s medicines regulator Sahpra says it’s on track to announce its registration decision by the end of October
The six-monthly anti-HIV jab is coming. But can SA keep track of millions of users?
The shot, called Lenacapavir, has a 100% success rate in preventing young women from getting HIV through sex
Two drugmakers will sell the 6-monthly anti-HIV jab for the price of the daily prevention pill
Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot around R692 per person a year
SA plans anti-HIV jab roll-out at hundreds of clinics by April
The health department hopes to make the twice-a-year anti-HIV injection lenacapavir available soon and to be buying generics by 2027
Small win for activists, but SA’s HIV projects won’t reopen
The $400 million the United States congress removed from a list of funding programmes the Trump administration wants to cut doesn’t cancel the cuts to HIV and TB programmes made…
SA gets R520 million to buy the twice-a-year anti-HIV jab – but there’s a snag
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it has already been awarded and was cut by 16% in June
The US’s NIH funds R6.65 billion of research in South Africa
If all of its National Institutes of Health funding falls away, the country could lose 70% of its medical research capacity
The six-monthly anti-HIV jab could end Aids in SA by 2032
A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s while